Creo Medical Group PLC
AIM:CREO 株式レポート
Creo Medical Group マネジメント Creo Medical Groupの CEO はCraig Gullifordで、 Jan2012年に任命され、 の在任期間は 12.83年です。 の年間総報酬は£ 881.66Kで、 34.6%給与と65.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.41%を直接所有しており、その価値は£ 305.88K 。経営陣と取締役会の平均在任期間はそれぞれ8.3年と6.4年です。
主要情報 CEO給与比率 34.6% CEO在任期間 12.8yrs CEOの所有権 0.4% 経営陣の平均在職期間 8.3yrs 取締役会の平均在任期間 6.4yrs
経営陣の近況
Chairman recently bought UK£700k worth of stock Oct 25
Creo Medical Group PLC, Annual General Meeting, Jun 26, 2024 Jun 02 Creo Medical Group plc Announces Board Changes May 15
Creo Medical Group PLC, Annual General Meeting, Jun 27, 2023 May 27
Key Executive recently bought UK£543k worth of stock Mar 15
Creo Medical Group PLC, Annual General Meeting, Mar 08, 2023 Feb 18
すべての更新を表示
New minor risk - Shareholder dilution Oct 27
Consensus EPS estimates fall by 24% Oct 25
Chairman recently bought UK£700k worth of stock Oct 25
Price target decreased by 28% to UK£0.57 Oct 24
New minor risk - Market cap size Oct 15
Consensus EPS estimates fall by 11% Oct 07
First half 2024 earnings released: UK£0.034 loss per share (vs UK£0.044 loss in 1H 2023) Oct 02
New minor risk - Shareholder dilution Oct 02
No longer forecast to breakeven Oct 01
New minor risk - Share price stability Sep 30 Micro-Tech (NL) International B.V. entered into a binding agreement to acquire 51% stake in Creo Medical, S.L.U. from Creo Medical Group PLC (AIM:CREO) for €36.7 million. Sep 20
Creo Medical Group PLC (LON:CREO) Screens Well But There Might Be A Catch Sep 19
New major risk - Financial position Sep 18
Creo Medical Group PLC, Annual General Meeting, Jun 26, 2024 Jun 02
Consensus EPS estimates fall by 21% May 22
Full year 2023 earnings: EPS and revenues miss analyst expectations May 16 Creo Medical Group plc Announces Board Changes May 15
Forecast to breakeven in 2026 May 07
New minor risk - Financial data availability May 03
Creo Medical Group PLC to Report Fiscal Year 2023 Results on May 15, 2024 Apr 26
New minor risk - Profitability Mar 11
Market Cool On Creo Medical Group PLC's (LON:CREO) Revenues Pushing Shares 26% Lower Mar 02
Creo Medical Group plc Announces Microwave Lung Ablation Update Mar 01
New minor risk - Share price stability Feb 07
Creo Medical Group plc Announces Continued Progress on the Phased Market Release of Its Latest Device, Speedboat® UltraSlim Feb 01
Forecast to breakeven in 2026 Dec 31
Revenues Tell The Story For Creo Medical Group PLC (LON:CREO) As Its Stock Soars 29% Dec 29
Creo Medical Group plc Announces First Use of Speedboat UltraSlim in the USA Dec 15
Creo Medical Group PLC Announces the Initiation of Its Commercial Launch of Speedboat Ultraslim Dec 13
Creo Medical Group plc Receives 510(K) Clearance from the Us Food & Drug Administration for Its Speedboat Ultraslim Device Nov 02
Creo Medical Group plc Announces EU Launch Accelerated by 18 Months Eu Regulatory Pathway for Launch Early 2024 Oct 26
Is Creo Medical Group (LON:CREO) Weighed On By Its Debt Load? Oct 06
First half 2023 earnings released: UK£0.044 loss per share (vs UK£0.074 loss in 1H 2022) Sep 17
Creo Medical Group PLC to Report First Half, 2023 Results on Sep 12, 2023 Sep 05
Creo Medical Group PLC, Annual General Meeting, Jun 27, 2023 May 27
Creo Medical Group plc Announces First In-Human Milestone Reaches for Microblate Flex as Part of Lung Tissue Ablation Clinical Study May 23
Full year 2022 earnings: EPS misses analyst expectations Apr 27
Key Executive recently bought UK£543k worth of stock Mar 15
Creo Medical Group PLC, Annual General Meeting, Mar 08, 2023 Feb 18 Creo Medical Group PLC has completed a Follow-on Equity Offering in the amount of £28.5 million. Feb 17
Creo Medical Group PLC, Annual General Meeting, Mar 08, 2023 Feb 16
Less than half of directors are independent Nov 16
Creo Medical Limited, Annual General Meeting, Jun 28, 2022 Jun 29
Creo Medical Limited to Report Fiscal Year 2021 Results on May 23, 2022 May 17
Less than half of directors are independent Apr 27
Creo Medical Limited has completed a Follow-on Equity Offering in the amount of £5.06601 million. Sep 08
Creo Medical Limited has completed a Follow-on Equity Offering in the amount of £31.250001 million. Aug 14
New 90-day high: UK£2.23 Feb 17
Creo Medical (LON:CREO) Is In A Good Position To Deliver On Growth Plans Feb 03
New 90-day high: UK£2.12 Jan 23
Creo Medical Group plc Receives US FDA clearance for MicroBlate™ Flex device Jan 08
How Many Creo Medical Limited (LON:CREO) Shares Do Institutions Own? Dec 09
New 90-day high: UK£2.08 Dec 09
New 90-day low: UK£1.67 Oct 13
First half earnings released Sep 29
New 90-day low: UK£1.72 Sep 19
CEO報酬分析 Creo Medical Group の収益と比較して、Craig Gulliford の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Jun 30 2024 n/a n/a -UK£22m
Mar 31 2024 n/a n/a -UK£22m
Dec 31 2023 UK£882k UK£305k -UK£22m
Sep 30 2023 n/a n/a -UK£23m
Jun 30 2023 n/a n/a -UK£25m
Mar 31 2023 n/a n/a -UK£26m
Dec 31 2022 UK£677k UK£280k -UK£27m
Sep 30 2022 n/a n/a -UK£28m
Jun 30 2022 n/a n/a -UK£28m
Mar 31 2022 n/a n/a -UK£26m
Dec 31 2021 UK£1m UK£280k -UK£25m
Sep 30 2021 n/a n/a -UK£23m
Jun 30 2021 n/a n/a -UK£21m
Mar 31 2021 n/a n/a -UK£21m
Dec 31 2020 UK£949k UK£280k -UK£20m
Sep 30 2020 n/a n/a -UK£19m
Jun 30 2020 n/a n/a -UK£17m
Mar 31 2020 n/a n/a -UK£17m
Dec 31 2019 UK£1m UK£675k -UK£16m
Jun 30 2019 n/a n/a -UK£13m
Mar 31 2019 n/a n/a -UK£12m
Dec 31 2018 UK£1m UK£792k -UK£10m
報酬と市場: Craigの 総報酬 ($USD 1.13M ) は、 UK市場 ($USD 363.49K ) の同規模の企業の平均を上回っています。
報酬と収益: Craigの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者 Mr. Craig Jonathan Gulliford serves as the Chief Executive Officer of Creo Medical Group plc since 2012. Mr. Gulliford served as Operations Director of Vix ACIS Limited (formerly ACIS Holdings Ltd). Mr. G ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 CEO & Executive Director 12.8yrs UK£881.66k 0.41% £ 305.9k Founder 22.8yrs UK£647.22k 1.2% £ 895.9k CFO & Executive Director 8.3yrs UK£650.61k 0.76% £ 564.8k Chief Commercial Officer & Executive Director 4.3yrs UK£664.76k 0.11% £ 81.9k Sales & Marketing Director no data データなし データなし Secretary less than a year データなし データなし
もっと見る
経験豊富な経営陣: CREOの経営陣は経験豊富で 経験豊富 です（平均在職期間は8.3年）。
取締役 名称 ポジション 在職期間 報酬 所有権 CEO & Executive Director 8.2yrs UK£881.66k 0.41% £ 305.9k Founder 8.2yrs UK£647.22k 1.2% £ 895.9k CFO & Executive Director 8.3yrs UK£650.61k 0.76% £ 564.8k Chief Commercial Officer & Executive Director 8yrs UK£664.76k 0.11% £ 81.9k Chairman less than a year データなし 0.89% £ 663.4k Senior Independent Non-Executive Director 3yrs UK£56.00k 0.34% £ 255.0k Independent Non-Executive Director 4.8yrs UK£56.00k 0.031% £ 23.2k Independent Non-Executive Director less than a year データなし データなし
もっと見る
経験豊富なボード: CREOの 取締役会 は 経験豊富 であると考えられます ( 6.4年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
